Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40119-017-0097-3 http://scihub22266oqcxt.onion/10.1007/s40119-017-0097-3 C5688974!5688974!28707043     free     free     free       Cardiol+Ther 2017 ; 6 (2): 175-81 Nephropedia Template TP {{tp|p=28707043|t=2017. Leadless Pacing: Current State and Future Direction |pdf=|usr=}}{{28707043}} gab.com Text Leadless Pacing: Current State and Future Direction JO: Cardiol Ther http://www.kidney.de/pget.php?&tw=1&pmid=28707043 #FOAvip Leadless pacing is now an established alternative to conventional pacing with subcutaneous pocket and transvenous lead for patients with class I or II single-chamber pacing indication. Available 12-month follow-up data shows a 48% fewer major complication rate in patients with Micra? compared to a historical control group in a nonrandomized study [1]. There is one system with Food and Drug Administration (FDA) approval and two with the Communauté Européenne (CE) mark. The OPS code for the implantation is 8?83d.3 and the procedure has recently been rated as a ?new Examination and Treatment Method (NUB)? in the German DRG system, meaning adequate reimbursement is negotiable with health insurance providers. The systems offer similar generator longevity and programming possibilities as conventional pacemaker systems, including rate response, remote monitoring, and MRI safety. The biggest downsides to date are limitations to single-chamber stimulation, lack of long-time data, and concerns of handling of the system at the end of its life span. However, implant procedure complication rates and procedure times do not exceed conventional pacemaker operations, and proper training and patient selection is provided. Twit Text FOAVip Leadless Pacing: Current State and Future Direction ????Cardiol Ther http://www.kidney.de/pget.php?&tw=1&pmid=28707043 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28707043 #FOAvip English Wikipedia <ref>{{Cite pmid|28707043}}</ref> Leadless Pacing: Current State and Future Direction #MMPMID28707043 Merkel M; Grotherr P; Radzewitz A; Schmitt C Cardiol Ther 2017[Dec]; 6 (2): 175-81 PMID28707043show ga Leadless pacing is now an established alternative to conventional pacing with subcutaneous pocket and transvenous lead for patients with class I or II single-chamber pacing indication. Available 12-month follow-up data shows a 48% fewer major complication rate in patients with Micra? compared to a historical control group in a nonrandomized study [1]. There is one system with Food and Drug Administration (FDA) approval and two with the Communauté Européenne (CE) mark. The OPS code for the implantation is 8?83d.3 and the procedure has recently been rated as a ?new Examination and Treatment Method (NUB)? in the German DRG system, meaning adequate reimbursement is negotiable with health insurance providers. The systems offer similar generator longevity and programming possibilities as conventional pacemaker systems, including rate response, remote monitoring, and MRI safety. The biggest downsides to date are limitations to single-chamber stimulation, lack of long-time data, and concerns of handling of the system at the end of its life span. However, implant procedure complication rates and procedure times do not exceed conventional pacemaker operations, and proper training and patient selection is provided. äLeadless Pacing: Current State and Future Direction (epmc).pdf DeepDyve Pubget Overpricing